Andrew J. Fromkin bought IMVT once, on Aug 10, 2021

Andrew J. Fromkin is a biopharmaceutical executive and corporate director who serves on the board of directors of Immunovant, Inc. and is classified as a director-level insider for the company.( He has been a member of Immunovant’s board since October 2019 and is identified in SEC and market filings as a Director (Dir.) and reporting insider for his equity holdings and trades in Immunovant stock.( In Immunovant’s governance structure, he also chairs the Compensation Committee of the board.(

Alongside his Immunovant role, Fromkin is a Vant Portfolio Operating Partner at Roivant Sciences, Inc., a position he has held since January 2021.( From January 2021 to April 2023 he served as Acting Chief Executive Officer of Proteovant Sciences, Inc.( Previously, he was Chief Executive Officer of Tarveda Therapeutics, Inc. (formerly Blend Therapeutics, Inc.) from March 2015 to September 2020.( From 2005 to 2011 he held multiple leadership roles at Clinical Data, Inc., including Executive Vice President (October 2005–May 2006) and later President, Chief Executive Officer, and Director (May 2006–May 2011).( Earlier in his career he served as President and CEO of DoctorQuality, Inc., President, CEO, and Director of Endo Surgical Devices, Inc., and Corporate Vice President, Business Development at Merck-Medco, a subsidiary of Merck & Co.; he began his career at Health Information Technologies, Inc. as General Manager of its MCA subsidiary and Director of Marketing and Payer Alliances.( He has also served on the board of Regado Biosciences, Inc., which became Tobira Therapeutics, Inc. in 2015.( Fromkin holds a B.A. from Brandeis University.(

Written by Perplexity from public sources.